Lexapro (Escitalopram) Dosing
For most adults with major depressive disorder (MDD) or generalized anxiety disorder (GAD), start Lexapro at 10 mg once daily and maintain this dose, as no additional benefit is seen at 20 mg daily. 1
Standard Adult Dosing
- Initial dose: 10 mg once daily 1
- Recommended maintenance dose: 10 mg once daily 1
- Maximum dose: 20 mg once daily 1
- Administration: Once daily, morning or evening, with or without food 1
The FDA label explicitly states that no additional benefits were observed at 20 mg once daily compared to 10 mg daily for both MDD and GAD 1. This is critical—most patients should remain at 10 mg rather than automatically escalating to higher doses.
Elderly Patients (≥60 years)
The recommended dose for elderly patients is 10 mg once daily and should not be increased. 1
- Maximum dose is capped at 10 mg daily in this population 1
- This restriction is based on concerns about QT prolongation, with escitalopram and citalopram showing dose-dependent cardiac effects 2
- Despite this dosing limitation, escitalopram at 10-20 mg/day has shown efficacy in elderly patients with comorbid depression and anxiety 3, though one study in patients ≥60 years failed to show statistical separation from placebo 4
Hepatic Impairment
Patients with hepatic impairment should receive 10 mg once daily as the maximum dose. 1
- Clearance of citalopram is decreased and plasma concentrations increased in hepatically impaired patients 1
- Do not exceed 10 mg daily regardless of response 1
Pediatric Dosing
For adolescents 12 years and older with MDD, and children 7 years and older with GAD:
- Initial dose: 10 mg once daily 1
- Recommended dose: 10 mg once daily 1
- Maximum dose: 20 mg once daily 1
Pregnant Patients
SSRIs including escitalopram can be continued during pregnancy when clinically indicated, but dosing should follow standard adult recommendations (10 mg daily). 2
- SSRIs do not increase risk of cardiac malformations despite earlier FDA concerns about paroxetine 2
- Late pregnancy SSRI exposure may increase risk of persistent pulmonary hypertension of the newborn (PPHN), with number needed to harm of 286-351 2
- SSRI exposure in the month before delivery is associated with less than 2-fold increase in postpartum hemorrhage risk 1
- The decision to treat must weigh maternal mental health benefits against potential fetal risks 2
Pharmacokinetic Considerations
- Time to steady state: 7-10 days 5
- Half-life: 27-33 hours, supporting once-daily dosing 5
- Time to peak concentration: 3-4 hours 5
- Bioavailability: 80%, not affected by food 6
- Protein binding: Low (56%), minimizing drug interaction risk 5
Dose Escalation in Non-Responders
If patients fail to achieve remission after 4 weeks at 10-20 mg daily, escalation to 30 mg daily may provide additional benefit for depressive symptoms, though this exceeds FDA-approved dosing. 7
- One study showed significantly greater MADRS score reduction with 30 mg versus 20 mg in non-remitters (p=0.046) 7
- However, response and remission rates did not differ significantly 7
- This approach should be reserved for treatment-resistant cases and requires careful cardiac monitoring given QT concerns 2, 8
Critical Safety Considerations
QT Prolongation
- Escitalopram causes dose-dependent QT prolongation 2
- Risk is particularly elevated in elderly patients, necessitating the 10 mg maximum dose in those >60 years 2, 1
- Avoid exceeding recommended doses and monitor ECG in high-risk patients 8
Renal Impairment
- Use with caution in severe renal impairment, though no specific dose adjustment is provided 1
- Escitalopram is extensively metabolized with minimal renal excretion of unchanged drug 1
Discontinuation
When stopping Lexapro, reduce the dose gradually whenever possible to minimize discontinuation symptoms. 1
This gradual taper helps prevent serotonin discontinuation syndrome 1.